Skip to main content
OpenTrials

Clinical trial condition

Fallopian Tube Neoplasms

Explore clinical trials studying Fallopian Tube Neoplasms. Study availability and eligibility vary by location and protocol.

600 public trials 90 recruiting studies
Refine in advanced search Browse all conditions

Fallopian Tube Neoplasms trial results

Completed

Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

NCT00074867

Conditions
Abdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, +19 more
Locations
  • Pfizer Investigational Site Los Angeles, California, United States
  • Pfizer Investigational Site Santa Monica, California, United States
  • Pfizer Investigational Site Baltimore, Maryland, United States
  • Pfizer Investigational Site Boston, Massachusetts, United States
View Trial Details
Completed

Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response

NCT00103545

Conditions
Abdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, +20 more
Locations
  • Clinic for Gynecology and Gyn. Oncology, Humboldt University Berlin, Germany
  • University Clinic Carl Gustav Carus, Gynecological hospital Dresden, Germany
  • Gynecologic Hospital Düsseldorf, Germany
  • University Gynecologic Hospital Essen, Germany
View Trial Details
Active, Not Recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02839707

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +33 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 920 locations
View Trial Details
Active, Not Recruiting

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

NCT05554328

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +21 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
View all 296 locations
View Trial Details
Active, Not Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

NCT04092270

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +43 more
Locations
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
View Trial Details
Active, Not Recruiting

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

NCT01116648

Conditions
Adnexal Diseases, Breast Diseases, Breast Neoplasms, +21 more
Locations
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois, United States
  • Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard Fort Wayne, Indiana, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

NCT04616534

Conditions
Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, +40 more
Locations
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details

Related conditions